We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
GW Pharmaceuticals (GWPH) Catches Eye: Stock Gains 6.2%
GW Pharmaceuticals plc was a big mover last session, as the company saw its shares rise over 6% on the day. The upside came as the company announced positive Phase 3 pivotal trial results for Epidiolex (cannabidiol) in the treatment of Lennox-Gastaut syndrome. This led to solid volume too with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $83.31 to $94.19 in the past one-month time frame, showed a pick-up yesterday at $88.49.
The company has seen no estimate revisions over the past 7 days, while the Zacks Consensus Estimate remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
GW Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
GW PHARMA-ADR Price
GW PHARMA-ADR Price | GW PHARMA-ADR Quote
A better-ranked stock in the same industry is Boston Scientific Corporation (BSX - Free Report) , which carries a Zacks Rank #2 (Buy).
Is GWPH going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>